Why Is Monash IVF Group (ASX:MVF) Share Price Up Today?

Sonal Goyal

01 September 2026 01:22 PM AEST

Why Is Monash IVF Group (ASX:MVF) Share Price Up Today?

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Highlights

Monash IVF (ASX:MVF) shares traded at $0.77, up 9.22% on 1 September 2026.
FY26 Revenue slipped 0.9% to A$269.5 million, while underlying NPAT dropped 41.2% to A$16.1 million.
The board maintained a fully franked 2.5-cent full-year Dividend despite the Earnings decline.
Softer fertility volumes and rising cost pressures were the primary drags on FY26 profitability.

Share Price Snapshot

Monash IVF Group (ASX:MVF) shares were trading at $0.77 on 1 September 2026, up 9.22% on the session. The move places MVF among the more actively traded names on the ASX healthcare boards that day.

Monash IVF Group is one of Australia's leading fertility services providers, operating a network of clinics, diagnostic laboratories and ultrasound services across Australia and internationally. The company has built its Business around assisted reproductive services, including IVF treatment cycles, genetic testing and specialist obstetric ultrasound, positioning it within a healthcare niche that has historically benefited from long-term demographic and lifestyle tailwinds, including delayed family formation and rising awareness of fertility treatment options.

The FY26 result revealed the operational challenges the company faced over the past year. Revenue came in at A$269.5 million, down 0.9% on the prior year, a relatively modest top-line decline. The more concerning figures sat further down the income statement: underlying EBITDA fell 19.5% to A$53.4 million, while underlying NPAT dropped 41.2% to just A$16.1 million. Management attributed the weaker profitability to softer fertility treatment volumes across its clinic network, combined with ongoing cost pressures that squeezed margins. Despite this, the board elected to declare a fully franked 2.5-cent full-year dividend, signalling confidence in the underlying cash generation of the business and a commitment to maintaining Shareholder returns through a softer earnings cycle.

Catalysts to Watch

Several catalysts could shape Monash IVF's trajectory from here. A recovery in fertility treatment volumes, potentially supported by seasonal Demand patterns or renewed Marketing and patient Acquisition efforts, would be the most direct lever for earnings improvement. Cost-management initiatives, including any restructuring of clinic operations or laboratory efficiencies, could also help rebuild margins without requiring a Volume recovery. Any bolt-on acquisitions or expansion into new geographic markets could provide a fresh growth narrative. Regulatory developments affecting fertility funding, Medicare rebates, or private Health Insurance coverage for IVF treatments are also worth monitoring, as these directly influence patient affordability and treatment volumes.

Key Risks

The fertility services sector remains sensitive to macroeconomic conditions. IVF treatment is a significant financial commitment for many patients, and cost-of-living pressures can lead to deferred or reduced treatment cycles, as appears to have occurred in FY26. Competitive dynamics also matter, given other established providers operate in the same market, and any loss of Market Share or pricing pressure could further compress margins. Given the sensitivity of fertility outcomes and treatment protocols, any adverse clinical, legal or reputational events could weigh on patient trust and referral volumes. Further cost Inflation without a corresponding volume recovery would continue to erode profitability.

Conclusion

Monash IVF Group's FY26 result told a story of a business under near-term pressure, with volume softness and cost inflation driving a substantial decline in underlying profitability. Separately, the stock's trading activity on 1 September 2026 showed a notable intraday gain. For investors, MVF represents a business with defensible long-term demand drivers in fertility services, but one that requires evidence of volume recovery and Margin discipline before the FY26 downturn can be considered fully behind it.

Q1: What was Monash IVF's share price on 1 September 2026?

Q2: What was Monash IVF's FY26 revenue?

Q3: Did Monash IVF declare a dividend for FY26?

Q4: What caused the drop in Monash IVF's profit?

Q5: What should investors watch for with MVF going forward?

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.